Rare Disease
Therapeutics Product
Portfolio

Approved treatments and
pipeline compounds

Rare Disease Therapeutics Product Portfolio

Approved treatments and pipeline compounds

RDT helps bring orphan drugs to market by partnering with companies to provide life-saving therapies for patients with rare diseases.

With over 30 years of experience in orphan drug commercialization, including experience in antivenoms, oncology, hematology, metabolic diseases, and genetic disorders, RDT maintains a foundational presence in rare disease outreach.

ANTIVENOM—FDA-APPROVED PRODUCTS

Name

Status

Links

ANTIVENOM—FDA-APPROVED PRODUCTS

Name

Status

Available

Links

Name

Status

Available

Links

ANTIVENOM—RESEARCH PRODUCTS

Name

Status

Links

ANTIVENOM—RESEARCH PRODUCTS

Name

Anawidow® Latrodectus Immune F(ab’)₂ (Equine) Injection

Status

BLA Pending

Links

HEMATOLOGY/ONCOLOGY—FDA-APPROVED PRODUCTS

Name

Status

Links

HEMATOLOGY/ONCOLOGY—FDA-APPROVED PRODUCTS

Name

Status

AVAILABLE

Links

Name

Status

AVAILABLE Q4 2024

Links

To report a suspected adverse reaction or to order any of our approved products, please call 1-844-472-7389.

If you prefer to report adverse reactions to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

To report a suspected adverse reaction or to order any of our approved products, please call 1-844-472-7389.

If you prefer to report adverse reactions to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Product History

Products previously sold by RDT

ORFADIN® (nitisinone) capsules

  • Orphan drug approved for the treatment of hereditary tyrosinemia type 1 (HT-1)
  • US distribution rights acquired by RDT in 1989
  • Pivotal clinical trials executed globally by RDT
  • Approved by the FDA in 1991
  • Transformed treatment of this rare disease
    • Replaced liver transplantation as the first-line treatment1
    • Liver failure is controlled in 90% of patients1

CYSTADANE® (betaine anhydrous for oral solution)

  • Specialty treatment approved for the treatment of homocystinuria in 1996
  • Previously available in small doses in health food stores, but RDT helped create a “medical-grade” dosage
  • Consulted and executed clinical trials for approval
  • Very small, but very at-risk patient population (~400 patients)

Reference:
1. McKiernan PJ (2006). “Nitisinone in the treatment of hereditary tyrosinaemia type 1”. Drugs. 66 (6): 743–750.